Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. medmico

MEDMICO

Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 MEDMICO project word cloud

Explore the words cloud of the MEDMICO project. It provides you a very rough idea of what is the project "MEDMICO" about.

integrating    patients    ready    central    evidenced    sensitivity    shelf    college    abnormalities    screen    contractor    radisens    submission    turbidimetry    tests    innovation    mode    prototype    projections    point    heart    diagnose    trials    workflow    disruptive    diagnostics    near    12    launch    regulatory    kidney    ischemic    usability    renal    majority    temperature    adult    cardiovascular    pipette    epidemic    1st    sub    immunoassays    optimal    provides    segments    primary    single    care    precision    diabetes    combat    disease    creatinine    positioning    efficient    outcomes    5    lipids    monitor    pilot    efficiencies    lab    date    validation    accuracy    population    counting    multiple    comorbidity    co    cell    panels    storage    comorbid    medmico    comorbidities    patient    life    expertise    rising    room    dublin    chemistry    away    diabetic    breakthrough    spearhead    incorporates    healthcare    hba1c    trinity    forefront    pharmacies    incumbent    diagnostic    2013    validated    gt    shift    complications    poct    3    morbid    outpatient    revenues    platform    quad    months    vitro    drive    laboratories    biomaterials    clinical    delivering    extensive    2035    trl8    clinics   

Project "MEDMICO" data sheet

The following table provides information about the project.

Coordinator		 RADISENS DIAGNOSTICS LIMITED 

Organization address
address: UNITS 1-3 WESTPOINT BUILDINGS LINK ROAD BALLINCOLL
city: CORK
postcode: IP31 HF29
website: www.radisens.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.radisens.com/
 Total cost 4˙487˙525 €
 EC max contribution 4˙487˙525 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RADISENS DIAGNOSTICS LIMITED IE (CORK) coordinator 4˙487˙525.00

Map

 Project objective

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from lab testing. The majority of current diagnostic testing for diabetes and comorbidities involves central laboratories as incumbent in-vitro diagnostic point-of-care testing (PoCT) provides sub-optimal accuracy and single tests (rather than needed panels) for diabetes and its comorbidities. MEDMICO will spearhead a diagnostic breakthrough by delivering the 1st quad-mode PoCT platform integrating immunoassays, turbidimetry, clinical chemistry and cell counting. HbA1c, Lipids and Creatinine tests will be integrated on to a single diabetes comorbid platform with state-of-the-art sensitivity/precision, room temperature storage, >12 months’ shelf-life and integrated pipette to screen, diagnose and monitor patients, within primary care, outpatient clinics and pharmacies. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this epidemic. MEDMICO incorporates extensive technical, clinical and exploitation expertise - Radisens’ disruptive PoCT prototype and Trinity College Dublin (sub-contractor) biomaterials expertise and diabetes patient access. MEDMICO’s potential is evidenced by Radisens’ revenues to date and large near-term projections from diagnostics partners before its launch. Existing research of end-user needs and workflow assessment will drive platform development and pilot production, with clinical validation and usability trials in multiple PoCT segments to TRL8. This will deliver a validated quad-mode diabetes comorbidity platform, ready for regulatory submission.

 Deliverables

List of deliverables.
Target stakeholder web site & project presentation Websites, patent fillings, videos etc. 2019-07-24 15:31:59

Take a look to the deliverables list in detail:  detailed list of MEDMICO deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDMICO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDMICO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More